Loading...

Cytokinetics

Nasdaq:CYTK
Snowflake Description

Adequate balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CYTK
Nasdaq
$646M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The last earnings update was 45 days ago. More info.


Add to Portfolio Compare Print
  • Cytokinetics has significant price volatility in the past 3 months.
CYTK Share Price and Events
7 Day Returns
17.4%
NasdaqGS:CYTK
5.9%
US Biotechs
2.2%
US Market
1 Year Returns
33.3%
NasdaqGS:CYTK
-4.3%
US Biotechs
3.8%
US Market
CYTK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cytokinetics (CYTK) 17.4% 11.4% 26.7% 33.3% 23.9% 130.9%
US Biotechs 5.9% 4.6% 1.7% -4.3% 22.4% 12%
US Market 2.2% 4.2% 4.4% 3.8% 43% 40.9%
1 Year Return vs Industry and Market
  • CYTK outperformed the Biotechs industry which returned -4.3% over the past year.
  • CYTK outperformed the Market in United States of America which returned 3.8% over the past year.
Price Volatility
CYTK
Industry
5yr Volatility vs Market

Value

 Is Cytokinetics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cytokinetics. This is due to cash flow or dividend data being unavailable. The share price is $11.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cytokinetics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cytokinetics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:CYTK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.93
NasdaqGS:CYTK Share Price ** NasdaqGS (2019-06-21) in USD $11.2
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cytokinetics.

NasdaqGS:CYTK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CYTK Share Price ÷ EPS (both in USD)

= 11.2 ÷ -1.93

-5.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cytokinetics is loss making, we can't compare its value to the US Biotechs industry average.
  • Cytokinetics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Cytokinetics's expected growth come at a high price?
Raw Data
NasdaqGS:CYTK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-7.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.04x
United States of America Market PEG Ratio Median Figure of 2,134 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cytokinetics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cytokinetics's assets?
Raw Data
NasdaqGS:CYTK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.06
NasdaqGS:CYTK Share Price * NasdaqGS (2019-06-21) in USD $11.2
United States of America Biotechs Industry PB Ratio Median Figure of 431 Publicly-Listed Biotechs Companies 3.01x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.81x
NasdaqGS:CYTK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CYTK Share Price ÷ Book Value per Share (both in USD)

= 11.2 ÷ 0.06

184.18x

* Primary Listing of Cytokinetics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cytokinetics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Cytokinetics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cytokinetics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cytokinetics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-7.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cytokinetics expected to grow at an attractive rate?
  • Unable to compare Cytokinetics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Cytokinetics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Cytokinetics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:CYTK Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:CYTK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -7.4%
NasdaqGS:CYTK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 19.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:CYTK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:CYTK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 57 -142 1
2021-12-31 57 -131 2
2020-12-31 32 -101 6
2019-12-31 31 -108 6
NasdaqGS:CYTK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 35 -98 -105
2018-12-31 32 -101 -106
2018-09-30 22 -113 -120
2018-06-30 18 -106 -131
2018-03-31 14 -111 -132
2017-12-31 13 -102 -128
2017-09-30 47 0 -80
2017-06-30 99 14 -14
2017-03-31 102 34 3
2016-12-31 106 37 16
2016-09-30 83 -51 0
2016-06-30 32 -49 -42

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cytokinetics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Cytokinetics's revenue is expected to grow by 19.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:CYTK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Cytokinetics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CYTK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -2.26 -2.26 -2.26 1.00
2021-12-31 -2.18 -2.18 -2.18 1.00
2020-12-31 -1.91 -1.73 -2.07 5.00
2019-12-31 -1.94 -1.88 -2.02 5.00
NasdaqGS:CYTK Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.93
2018-12-31 -1.95
2018-09-30 -2.22
2018-06-30 -2.42
2018-03-31 -2.52
2017-12-31 -2.59
2017-09-30 -1.74
2017-06-30 -0.34
2017-03-31 0.08
2016-12-31 0.41
2016-09-30 0.00
2016-06-30 -1.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cytokinetics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Cytokinetics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cytokinetics has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cytokinetics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cytokinetics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cytokinetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cytokinetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cytokinetics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cytokinetics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cytokinetics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CYTK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 34.70 -105.37 31.46
2018-12-31 31.50 -106.29 31.28
2018-09-30 22.11 -120.31 33.98
2018-06-30 17.65 -130.65 37.23
2018-03-31 14.48 -132.20 37.62
2017-12-31 13.37 -127.79 36.47
2017-09-30 46.52 -80.15 32.88
2017-06-30 99.39 -14.43 30.45
2017-03-31 102.14 3.04 29.10
2016-12-31 106.41 16.45 27.82
2016-09-30 83.03 0.07 26.68
2016-06-30 31.92 -42.14 24.74
2016-03-31 32.67 -41.08 22.14
2015-12-31 28.66 -37.50 19.67
2015-09-30 40.66 -19.83 18.70
2015-06-30 42.13 -16.95 17.41
2015-03-31 43.38 -14.77 17.38
2014-12-31 46.94 -14.65 17.27
2014-09-30 49.53 -16.56 16.80
2014-06-30 44.59 -23.18 16.45
2014-03-31 37.81 -29.84 15.72
2013-12-31 30.65 -33.72 15.09
2013-09-30 8.48 -51.70 14.81
2013-06-30 5.73 -49.16 14.17
2013-03-31 6.56 -44.37 13.01
2012-12-31 7.56 -41.68 12.43
2012-09-30 6.13 -42.10 11.48
2012-06-30 5.84 -42.69 11.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cytokinetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cytokinetics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cytokinetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cytokinetics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cytokinetics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cytokinetics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cytokinetics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cytokinetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cytokinetics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cytokinetics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cytokinetics Company Filings, last reported 2 months ago.

NasdaqGS:CYTK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 3.37 52.37 176.62
2018-12-31 25.93 42.41 198.73
2018-09-30 52.07 41.91 210.31
2018-06-30 75.17 32.37 231.94
2018-03-31 99.60 31.95 251.45
2017-12-31 109.84 31.78 268.89
2017-09-30 147.04 30.30 307.57
2017-06-30 175.00 30.16 312.05
2017-03-31 95.38 30.02 206.56
2016-12-31 94.36 29.88 156.25
2016-09-30 84.73 29.74 78.61
2016-06-30 48.75 29.60 90.34
2016-03-31 57.91 29.47 103.42
2015-12-31 68.59 14.64 111.44
2015-09-30 67.30 0.00 97.99
2015-06-30 74.86 0.00 105.18
2015-03-31 84.15 0.00 107.87
2014-12-31 92.06 0.00 83.23
2014-09-30 73.63 0.00 78.50
2014-06-30 78.70 0.00 77.75
2014-03-31 86.18 0.00 82.35
2013-12-31 54.44 0.00 77.73
2013-09-30 39.75 0.00 81.64
2013-06-30 51.99 0.00 75.65
2013-03-31 58.43 0.00 61.60
2012-12-31 70.09 0.00 74.00
2012-09-30 80.60 0.00 75.61
2012-06-30 89.98 0.00 90.48
  • Cytokinetics's level of debt (1263.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1263.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cytokinetics has sufficient cash runway for 1.8 years based on current free cash flow.
  • Cytokinetics has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 54.3% each year.
X
Financial health checks
We assess Cytokinetics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cytokinetics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cytokinetics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cytokinetics dividends.
If you bought $2,000 of Cytokinetics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cytokinetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cytokinetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:CYTK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:CYTK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cytokinetics has not reported any payouts.
  • Unable to verify if Cytokinetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cytokinetics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cytokinetics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cytokinetics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cytokinetics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cytokinetics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cytokinetics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Robert Blum
COMPENSATION $3,265,575
AGE 54
TENURE AS CEO 12.4 years
CEO Bio

Mr. Robert I. Blum has been President and Chief Executive Officer of Cytokinetics, Incorporated since January 22, 2007. Mr. Blum previously served as President from February 2006 to January 2007, Executive Vice President, Corporate Development and Commercial Operations and Chief Business Officer from September 2004 to February 2006, Executive Vice President, Corporate Development and Finance and Chief Financial Officer from January 2004 to September 2004, Senior Vice President, Corporate Development and Finance and Chief Financial Officer from October 2001 to December 2003 and Vice President, Business Development from July 1998 to September 2001 at Cytokinetics, Incorporated and also served as its Principal Accounting Officer and Secretary. Prior to joining Cytokinetics in July 1998, he held senior positions in Business Development and Marketing at COR Therapeutics from 1991 to 1998. He served as Director, Marketing at COR Therapeutics, Inc., a biopharmaceutical company, since 1996. From 1991 to 1996, he was Director, Business Development at COR Therapeutics. Prior to that, Mr. Blum performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion Laboratories, Inc. and Syntex Corporation from 1981. Mr. Blum has been Director of Cytokinetics, Incorporated since January 22, 2007. He has been Chairman of Gamida Cell Ltd. since September 18, 2018. He serves on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools designed to further science education and exploration in the spirit of repairing the world. Mr. Blum serves on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He has also served on the Boards of San Francisco's Contemporary Jewish Museum and the Anti-Defamation League. He is on faculty at the Center for BioEntrepreneurship at UC San Francisco where he has taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. Mr. Blum was named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School.

CEO Compensation
  • Robert's compensation has increased whilst company is loss making.
  • Robert's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Cytokinetics management team in years:

6.2
Average Tenure
57
Average Age
  • The average tenure for the Cytokinetics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Robert Blum

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
54
TENURE
12.4 yrs

Ching Jaw

TITLE
Senior VP & CFO
COMPENSATION
$954K
AGE
55
TENURE
2 yrs

Dave Cragg

TITLE
Senior Vice President of Human Resources
COMPENSATION
$980K
AGE
62
TENURE
9.9 yrs

Fady Malik

TITLE
Executive Vice President of Research & Development
COMPENSATION
$2M
AGE
54
TENURE
7 yrs

Jim Spudich

TITLE
Co-Founder & Member of Scientific Advisory Board
COMPENSATION
$22K
AGE
76
TENURE
21.8 yrs

Robert Wong

TITLE
VP & Chief Accounting Officer
AGE
51
TENURE
0.1 yrs

Diane Weiser

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
4.1 yrs

Bonnie Charpentier

TITLE
Senior Vice President of Regulatory Affairs & Compliance
COMPENSATION
$1M
AGE
66
TENURE
5.4 yrs

Mark Schlossberg

TITLE
Senior VP of Legal & General Counsel
AGE
57
TENURE
0.4 yrs

Andy Wolff

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$728K
AGE
63
TENURE
14.8 yrs
Board of Directors Tenure

Average tenure and age of the Cytokinetics board of directors in years:

8.6
Average Tenure
67.5
Average Age
  • The tenure for the Cytokinetics board of directors is about average.
Board of Directors

Pat Gage

TITLE
Chairman
COMPENSATION
$281K
AGE
76
TENURE
9.3 yrs

Robert Blum

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
54
TENURE
12.4 yrs

Jim Spudich

TITLE
Co-Founder & Member of Scientific Advisory Board
COMPENSATION
$22K
AGE
76

James Sabry

TITLE
Co-Founder & Chairman of Scientific Advisory Board
COMPENSATION
$42K
AGE
59
TENURE
11.2 yrs

Sandy Costa

TITLE
Director
COMPENSATION
$188K
AGE
72
TENURE
8.6 yrs

Wendell Wierenga

TITLE
Director
COMPENSATION
$215K
AGE
70
TENURE
8.3 yrs

B. Parshall

TITLE
Director
COMPENSATION
$207K
AGE
64
TENURE
6.3 yrs

Ron Vale

TITLE
Member of Scientific Advisory Board

Thomas Pollard

TITLE
Member of Scientific Advisory Board

David Morgans

TITLE
Member of Scientific Advisory Board
COMPENSATION
$942K
AGE
65
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Cytokinetics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cytokinetics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What You Must Know About Cytokinetics, Incorporated's (NASDAQ:CYTK) Beta Value

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one. … What this means for you: Beta only tells us that the Cytokinetics share price is sensitive to broader market movements.

Simply Wall St -

Could Cytokinetics, Incorporated's (NASDAQ:CYTK) Investor Composition Influence The Stock Price?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

If You Had Bought Cytokinetics (NASDAQ:CYTK) Shares Three Years Ago You'd Have Made 27%

Given that Cytokinetics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … In the last 3 years Cytokinetics saw its revenue shrink by 24% per year. … The falling revenue is arguably somewhat reflected in the lacklustre return of 8.3% per year over three years, which falls short of the market return.

Simply Wall St -

What Should We Expect From Cytokinetics, Incorporated's (NASDAQ:CYTK) Earnings In The Years Ahead?

Help shape the future of investing tools and receive a $20 prize! … In December 2018, Cytokinetics, Incorporated (NASDAQ:CYTK) announced its most recent earnings update, which … that losses became smaller relative to the prrior year's level

Simply Wall St -

How Should Investors React To Cytokinetics Incorporated's (NASDAQ:CYTK) CEO Pay?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Robert Blum's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Cytokinetics Incorporated has a market cap of US$433m, and is paying total annual CEO compensation of US$2.9m.

Simply Wall St -

How Does Cytokinetics Incorporated (NASDAQ:CYTK) Affect Your Portfolio Volatility?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Is Cytokinetics Incorporated's (NASDAQ:CYTK) CEO Incentives Align With Yours?

Leading Cytokinetics Incorporated (NASDAQ:CYTK) as the CEO, Robert Blum took the company to a valuation of US$403.77m. … Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … CEOs leading companies of similar size and profitability

Simply Wall St -

How Does Cytokinetics Incorporated (NASDAQ:CYTK) Affect Your Portfolio Returns?

Generally, an investor should consider two types of risk that impact the market value of CYTK. … The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few.

Simply Wall St -

Is Cytokinetics Incorporated (NASDAQ:CYTK) Expensive For A Reason? A Look At The Intrinsic Value

The sum of these cash flows is then discounted to today's value. … 5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF ($, Millions) $-112.20 $-92.80 $-79.30 $-28.90 $77.10 Source Analyst x1 Analyst x1 Analyst x1 Analyst x1 Analyst x1 Present Value Discounted @ 11.61% $-100.53 $-74.49 $-57.03 $-18.62 $44.51 Present Value of 5-year Cash Flow (PVCF)= $-206 We now need to calculate the Terminal Value, which accounts for all the future cash flows after the five years. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = $77 × (1 + 2.5%) ÷ (11.6% – 2.5%) = $864 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = $864 / ( 1 + 11.6%)5 = $499 The total value, or equity value, is then the sum of the present value of the cash flows, which in this case is $293.

Simply Wall St -

What Should You Know About Cytokinetics Incorporated's (NASDAQ:CYTK) Long Term Outlook?

Below, I've presented key growth figures on how market analysts predict Cytokinetics's earnings growth trajectory over the next few years and whether the future looks brighter. … The slope of this line is the rate of earnings growth, which in this case is 31.78%. … This means, we can anticipate Cytokinetics will grow its earnings by 31.78% every year for the next couple of years.

Simply Wall St -

Company Info

Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

Details
Name: Cytokinetics, Incorporated
CYTK
Exchange: NasdaqGS
Founded: 1997
$646,478,403
57,721,286
Website: http://www.cytokinetics.com
Address: Cytokinetics, Incorporated
280 East Grand Avenue,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CYTK Common Stock Nasdaq Global Select US USD 29. Apr 2004
DB KK3A Common Stock Deutsche Boerse AG DE EUR 29. Apr 2004
Number of employees
Current staff
Staff numbers
130
Cytokinetics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/23 23:51
End of day share price update: 2019/06/21 00:00
Last estimates confirmation: 2019/05/10
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.